Cohort of Patients With Systemic Sclerosis and Associated Biological Collection Within the Framework of the RESO Reference Centre for Rare Systemic Autoimmune Diseases

Status: Recruiting
Location: See location...
Intervention Type: Other, Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc. However, one of the keys to conducting quality research on this disease remains the development of well-documented patient cohorts with reliable biological samples. The main objective of this cohort is to study the natural progression of SSc in a cohort of patients followed over 5 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient over 18 years old

• Patient with systemic scleroderma according to the ACR/EULAR 2013 criteria, or with a very early systemic sclerosis defined by the presence of Raynaud's phenomenon and auto-antibodies in blood sample (ACAN positivity (≥1/160) with anti-Scl70, anti-centromere or anti-ARNPolIII specificity).

• Person affiliated or benefiting from a social security scheme.

• Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research)

Locations
Other Locations
France
CHU de Bordeaux - service de rhumatologie
RECRUITING
Bordeaux
Contact Information
Primary
Marie-Elise TRUCHETET, MD, PhD
marie-elise.truchetet@chu-bordeaux.fr
05.56.79.55.56
Backup
Thomas BARNETCHE, PhD
thomas.barnetche@chu-bordeaux.fr
05.57.82.04.93
Time Frame
Start Date: 2020-06-08
Estimated Completion Date: 2034-06
Participants
Target number of participants: 500
Treatments
Experimental: subjects SSc diagnosed
Patient with systemic scleroderma according to the American College of Rheumatology (ACR) / EULAR 2013 criteria
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Bordeaux

This content was sourced from clinicaltrials.gov